SCHEMBL27764190

SCHEMBL27764190

CN1CC(N)CCC1C=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27764189 1.00 — —
SCHEMBL27764215 1.00 — —
SCHEMBL12719881 0.80 — —
SCHEMBL3695582 0.76 — —
SCHEMBL13865292 0.76 — —
SCHEMBL28176953 0.74 — —
SCHEMBL28821530 0.69 — —
SCHEMBL31029450 0.69 — —
SCHEMBL2089866 0.69 — —
SCHEMBL25813854 0.69 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107635986-A Substituted quinoxaline derivatives 赛尔维他股份公司 2018-01-26 — — CN disclosed
CN-104321325-B Pyrrolopyrrole alkanone compound 诺华股份有限公司 2016-11-16 — — CN disclosed
CN-104203952-B Imidazo pyrrolidone-2 compounds 诺华股份有限公司 2016-10-19 — — CN disclosed
CN-103214481-B Novel imidazole also [1,2-a] pyridine compounds and their, its preparation method, comprise the medical composition and its use of this compounds 中国科学院上海药物研究所 2016-08-03 — — CN disclosed
CN-104321325-A Pyrrolopyrrolidinone compounds NOVARTIS AG 2015-01-28 — — CN disclosed
CN-104203952-A Imidazopyrrolidinone compounds NOVARTIS AG 2014-12-10 — — CN disclosed
CN-103214481-A Novel imidazo[1,2-a]pyridines compound, preparation method, pharmaceutical composition containing imidazo[1,2-a]pyridines compound and application SHANGHAI INST MATERIA MEDICA 2013-07-24 — — CN disclosed
CN-102159548-A Amide compounds useful in therapy PFIZER LTD 2011-08-17 — — CN disclosed
CN-101426505-A Dihydrothienopyrimidine for treating inflammatory disorders BOEHRINGER INGELHEIM INT (DE) 2009-05-06 — — CN disclosed
Send feedback